Fast Track Initiative, Inc

About us

FTI Venture Partners is a biotech-focused venture capital firm that has offices in Tokyo and Boston. We find out, invest, and grow transformative early-stage companies across healthcare sectors. Over 15 years of investment experience, we have managed a total of $100M and grown 20+ innovative companies.

Our Approach

  • Invest in life science and healthcare companies that are backed by innovative platform technologies
  • Start investment at early-stage, typically from Seed to Series A, and follow on at later rounds
  • Serve as an active investor and drive value through operational involvement

Our Differentiation

  • Facilitate impactful partnership creation through top-tier network with Asian/Japanese life science/healthcare industry
  • Assist startups realize key academic collaborations with top institutions
  • Support startups innovate the regulatory frontier via our close relationship with the regulator
  • Provide hands-on, operational support to drive startups’ initial growth

Our Approach

  • Pharma and life science investment professionals with extensive experiences in industries and academia
  • Substantial network with leaders and experts in industry, academia, medical and regulatory KOLs

Companies (Partial)

Fund II Portfolio

ロゴマーク:株式会社モダリス(旧:エディジーン株式会社)

MA, USA and Tokyo, Japan

Transformative gene modulation platform with its proprietary, multi-functional Cas proteins. Spin-out from Univ of Tokyo. IPOed in 2020

ロゴマーク:アキュルナ株式会社

Tokyo, Japan

Augmenting the ability of nucleic acid therapies using poly- micelle delivery. Proven efficiency with long and short nucleic acid chain. Acquired in 2020

ロゴマーク:モジュラス株式会社

MA, USA and Tokyo, Japan

Early-stage drug discovery through the global integration of large-scale GPU simulations and unique biological insights

ロゴマーク:株式会社ブレイゾン・セラピューティクス

MA, USA and Tokyo, Japan

Innovative drug delivery for CNS diseases. Glucose ligand- modified micelles have substantial ability to cross BBB

ロゴマーク:PuREC株式会社

Shimane, Japan

Cell therapy with highly purified Mesenchymal Stem Cells. Operates proprietary cell analysis and growth prediction engine to select most viable MSCs

ロゴマーク:株式会社PENTAS

Tokyo, Japan

Clinical-stage medical device company developing stent and microcatheter in combination with fluid simulation software

ロゴマーク:リーズンホワイ株式会社

Tokyo, Japan

Operating oncology KOL database and developing patient services: Doctor-to-Patient (D2P) matching platform and cancer-specific insurance partnering an insurance company

ロゴマーク:株式会社メンタルヘルステクノロジーズ

Tokyo, Japan

Medical agency service that dispatches psychiatrists to corporates to support employees mental health

ロゴマーク:株式会社ユカシカド

Tokyo, Japan

Personalized nutrition management service. Direct-to- consumer (D2C) urine test and personalized supplement

Fund I Portfolio

ロゴマーク:株式会社カイオム・バイオサイエンス

Tokyo, Japan

mAb discovery and optimization platform harnessing cell- based technology. Alliance with Chugai Pharmaceuticals. IPOed in 2011

ロゴマーク:株式会社セルシード

Tokyo, Japan

Cell sheet technology that enables variety of tissue products including cornea, cardiac patch, cartilage sheet. IPOed in 2010

ロゴマーク:株式会社医療情報総合研究所

Tokyo, Japan

First integrated database and analysis for medical prescription. Exclusive use of over 10 million prescription. Acquired in 2012